Combined Chelation Therapy With Deferasirox and Desferrioxamine in Removing Lead From Rats

Abstract

The present study aimed to evaluate the potential efficiency of Deferasirox (DFX) and Desfferioxamine (DFO) as chelating agents in removing lead from rats as a biological model. Two different doses of lead (II) chloride (40 and 80 mg kg −1 body weight) were used for 45 days. After this period, all rats showed toxicity symptoms through loss of hair, greenish mottling on the liver, appearance of red dots around eyes and weakness. After lead administration, chelation therapy was done in removing the toxic metal from the biological system. The abilities of DFX and DFO chelators in removal of lead from the body were studied for 10 days. Lead and iron concentrations in different tissues were measured by Flame Atomic Absorption Spectroscopy (FAAS). Our results showed that two chelators can be more effective as combined therapy than as single therapy in removing lead from the body and also, toxicity symptoms are decreased. It could be concluded that DFX and DFO chelators could be used for the treatment of complication of lead intoxication symptoms.

Anti-leukemic properties of deferasirox via apoptosis in murine leukemia cell lines

“…Deferoxamine (DFO) and deferasirox (DFX) are ICAs with different iron-chelating mechanisms. DFO has a short half-life, and must be injected intravenously or subcutaneously, because it is a large and highly hydrophilic molecule [ 7 , 8 ]. In contrast, DFX has relatively high lipophilicity and is an orally administered iron chelator that was developed to treat transfusional iron overload.…”

“…In contrast, DFX has relatively high lipophilicity and is an orally administered iron chelator that was developed to treat transfusional iron overload. Previous work indicates that DFX is safe and effective for the reduction of iron overload [ 8 , 9 ].…”